IOSR Journal Of Pharmacy And Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 15, Issue 1 Ser. IV (Jan –Feb 2020), PP 59-64
www.Iosrjournals.Org

Next-Generation Pharmacovigilance: AI, Real-World Evidence, and Global Harmonization for Proactive Drug Safety Monitoring

Vani Pathuri
Pharmacovigilance Department, Unicon Pharma Inc, Hillsborough, New Jersey, United States Of America.

Abstract
Pharmacovigilance regulations have evolved significantly since their inception in the mid-20th century, driven by the need to ensure drug safety amidst growing therapeutic complexity. By 2020, regulatory frameworks emphasize lifecycle monitoring, global harmonization, and integration of advanced technologies. Current challenges include underreporting of adverse drug reactions (ADRs), data heterogeneity, and the demands of accelerated drug approvals. Emerging trends such as artificial intelligence (AI), real-world evidence (RWE), and distributed database networks are poised to transform pharmacovigilance into a proactive, predictive discipline. This paper analyzes the historical trajectory of pharmacovigilance regulations, evaluates 2020's systemic challenges, and proposes future regulatory directions anchored in technological innovation and international collaboration. The discussion highlights the imperative for adaptive policies to address novel therapies, pandemic-driven urgency, and patient-centric safety paradigms.

Keywords: *Pharmacovigilance, regulatory frameworks, real-world evidence, artificial intelligence, global collaboration, adverse drug reactions, vaccine safety, risk management, post-marketing surveillance, data integrity.*

I. Introduction

Pharmacovigilance has become a key discipline following the thalidomide catastrophe of the 1960s, which caused severe congenital malformations in thousands of infants globally. This tragedy exposed systemic gaps in post-marketing drug safety monitoring and catalyzed the establishment of formal regulatory frameworks. The 1962 Kefauver-Harris Amendment in the United States mandated proof of efficacy and safety for new drugs, while the World Health Organization (WHO) launched the International Program for Drug Monitoring in 1968 to standardize adverse event reporting. By 2020, pharmacovigilance has expanded beyond spontaneous reporting systems (SRS) to encompass electronic health records (EHRs), social media analytics, and AI-driven signal detection.[2]

The necessity of pharmacovigilance lies in its role as a safeguard against both known and unforeseen risks. Pre-marketing clinical trials, though rigorous, are limited by homogeneous patient cohorts, short durations, and controlled environments, often failing to detect rare or long-term ADRs. Post-marketing surveillance thus remains indispensable for characterizing drug safety in real-world populations, particularly for biologics, vaccines, and advanced therapies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) now enforce lifecycle monitoring through risk evaluation and mitigation strategies (REMS) and Good Pharmacovigilance Practices (GVP).

The regulatory environment in 2020 faces unprecedented challenges. Globalization of pharmaceutical supply chains necessitates harmonized standards, yet disparities persist in resource-limited regions, where underreporting rates exceed 90%. Concurrently, accelerated approval pathways for breakthrough therapies—exemplified by orphan drugs and mRNA vaccines—demand robust post-marketing frameworks to mitigate risks. The COVID-19 pandemic further intensifies these pressures, as emergency-use authorizations for repurposed drugs like hydroxychloroquine highlight the dangers of off-label use without robust safety data. [3]

Future regulatory evolution will hinge on addressing these challenges through technological integration, enhanced data interoperability, and global cooperation. This paper looks at the trajectory of pharmacovigilance regulations, their 2020 challenges, and evidence-based policy recommendations to fortify drug safety in an era of rapid therapeutic innovation.

II. Literature Review

Initially, pharmacovigilance frameworks were largely reactive, relying on voluntary adverse drug reaction (ADR) reporting through spontaneous reporting systems (SRS). The establishment of the WHO's Uppsala Monitoring Centre in 1978 provided a centralized mechanism for global signal detection, facilitating early efforts in cross-border pharmacovigilance harmonization [4]. However, as drug development accelerated in the 1990s, limitations of passive surveillance mechanisms became apparent, prompting regulatory bodies to mandate proactive pharmacovigilance planning. The International Council for Harmonisation (ICH) E2E guidelines of 2004 required manufacturers to integrate risk minimization strategies into drug development pipelines, thereby transitioning pharmacovigilance from a reactive paradigm to a more structured risk management framework [5]. Further advancements came to light in the late 2000s with initiatives such as the FDA's Sentinel Initiative (2008), which pioneered real-time drug safety surveillance through distributed database networks [6].

Despite these regulatory advancements, pharmacovigilance systems face persistent challenges in data integration, signal validation, and global standardization. The underreporting of ADRs remains a critical bottleneck, with studies estimating that only 5–10% of ADRs are formally documented, particularly in resource-limited settings [7,8]. Furthermore, the globalization of pharmaceutical supply chains has introduced disparities in pharmacovigilance capabilities, as low- and middle-income countries (LMICs) struggle with limited infrastructure and workforce constraints, leading to gaps in post-marketing surveillance [10]. The advent of advanced therapy medicinal products (ATMPs), including gene and cell-based therapies, adds further complexity, as these interventions often receive conditional approvals based on limited clinical trial data, necessitating long-term safety monitoring post-commercialization [9]. Additionally, the proliferation of digital therapeutics (DTx) has introduced new challenges, as these interventions lack standardized pharmacovigilance protocols, raising concerns regarding data security and adverse event reporting [11]. Addressing these challenges requires a paradigm shift toward AI-driven surveillance, real-world evidence (RWE) integration, and global harmonization initiatives to ensure robust, real-time pharmacovigilance mechanisms in an era of rapid biomedical innovation [12,13].

Historical Evolution of Pharmacovigilance Regulations

The foundational era of pharmacovigilance (1960s–1980s) focused on reactive surveillance via SRS, where healthcare professionals voluntarily reported suspected ADRs. The WHO's Uppsala Monitoring Centre, established in 1978, became a global repository for ADR data, enabling cross-national signal detection. By the 1990s, regulatory frameworks began emphasizing proactive risk management. The International Council for Harmonisation (ICH) E2E guidelines (2004) mandated pharmacovigilance planning during drug development, requiring manufacturers to submit risk minimization strategies. [4, 5]

The 2010s saw the rise of risk-based monitoring, driven by the FDA's Sentinel Initiative (2008), which used distributed database networks to analyze EHRs and claims data from millions of patients. EMA's 2012 GVP modules further standardized processes for signal validation, periodic safety update reports (PSURs), and risk communication [5]. These advancements showcase a shift from passive data collection to active surveillance, particularly for vaccines and biologics, where lot-specific tracking became mandatory. [6]

Current Challenges in 2020

- Underreporting and Data Fragmentation: Only 5–10% of ADRs are reported globally, with lower rates in developing nations due to limited awareness and infrastructure 618. Disparate data formats across regions impede signal detection, as exemplified by inconsistent coding of ADRs in EHRs. [7] [8]
- Accelerated Approvals and Novel Therapies: Advanced therapy medicinal products (ATMPs), including gene therapies, often receive conditional approvals based on small trials, leaving long-term safety uncertainties. For example, CAR-T cell therapies carry risks of cytokine release syndrome and neurotoxicity, requiring extended post-marketing follow-up. [9]
- Global Inequities: Vaccine manufacturers in new economies, despite adhering to WHO prequalification standards, face resource constraints in maintaining pharmacovigilance systems comparable to those in high-income countries. A recent survey of 34 manufacturers revealed gaps in signal management and quality control [10].
- Digital Therapeutics (DTx) and AI: DTx, such as cognitive behavioral therapy apps, lack standardized pharmacovigilance protocols. While adverse events are typically milder than those of conventional drugs, data privacy concerns and variable app quality complicate monitoring. [11]
- Pandemic-Driven Pressures: The COVID-19 crisis has accelerated drug repurposing and vaccine development, straining existing pharmacovigilance systems. Off-label use of azithromycin and hydroxychloroquine, despite cardiac risks, illustrates the peril of rapid adoption without sufficient safety data. [7, 8, 9, 10, 11]

Future Regulatory Directions

Regulatory bodies are anticipated to mandate the integration of advanced artificial intelligence (AI) and machine learning (ML) tools for automated adverse drug reaction (ADR) extraction from a variety of data sources, including electronic health records (EHRs), social media platforms, and clinical narratives. In this evolving landscape, natural language processing (NLP) algorithms are already being used to parse unstructured text, thereby converting free- form clinical notes into standardized terminologies that facilitate quantitative signal detection. [12]

New machine learning models, such as Bayesian neural networks, are expected to further refine signal prioritization by quantitatively assessing the probability that a given pattern represents a true safety signal rather than a coincidental finding or noise. [13]

Era	Key Regulatory Initiatives/Regulations	Specific Examples/Details
Past	● ICH E2B Guidelines (pre- R3) ● FDA Sentinel Initiative (Mini-Sentinel Phase, 2008)	● ICH E2B established standardized formats for Individual Case Safety Reports (ICSRs) ensuring a uniform approach to ADR reporting. ● The Mini-Sentinel pilot (initiated in 2008) laid the groundwork for a distributed electronic surveillance system, expressing the feasibility of real-time signal detection using existing claims data.
Present	● Full FDA Sentinel System (launched 2016) ● EMA's 2020 Guidance on Patient-Reported Outcomes (PROs) ● Implementation of RWE frameworks via OHDSI and OpenSAFELY ● Italian VALORE Project	● The Sentinel System now comprises a nationwide multisite distributed database used for advanced signal detection and causal analysis in drug safety. ● EMA's guidance mandates the integration of PRO data in benefit-risk assessments, enhancing patient-centric pharmacovigilance. ● RWE frameworks from OHDSI and OpenSAFELY are currently being used to supplement clinical trial data, providing broader safety insights from routine care. ● The VALORE project has shown the power of multi-database networks in postmarketing surveillance of biological drugs in Italy.
Future	● Mandatory AI/ML-Driven ADR Extraction and Signal Prioritization ● Regulatory Requirements for RWE Integration from Distributed Networks ● Global Harmonization through WHO Global Vaccine Safety Blueprint 2.0 and EU ACCESS Project ● Embedded Risk Management for ATMPs (including wearable devices) ● Enhanced PRO Reporting via mHealth Platforms	● Future regulations are expected to require that companies deploy AI tools—such as dynamic graph convolutional networks and Bayesian neural networks—to automatically extract and prioritize ADR signals from diverse data sources. ● New guidelines will mandate that RWE from networks like OHDSI and OpenSAFELY be systematically used in safety assessments, with performance benchmarks established by initiatives like the Sentinel System. ● Global harmonization efforts will enforce standardized ADR reporting (e.g., via the expanded WHO Global Vaccine Safety Blueprint 2.0 and EU ACCESS project) across low-resource and developed regions. ● Advanced therapies will be subject to strict RMPs that include real-time monitoring using wearable devices for early detection of adverse events. ● Regulatory bodies will require pharmaceutical companies to implement validated, patient-centric mHealth applications to capture PRO data, ensuring that underreported subjective adverse events are fully integrated into safety evaluations.

Table 1: Past, Present, and Future Regulatory Initiatives [4, 7, 8, 10, 11, 13]

The efficacy of distributed analytics, as expressed by initiatives like the FDA's Sentinel Initiative, highlights the potential for these AI systems to expedite the identification of rare ADRs and to improve their accuracy across large-scale, geographically diverse datasets. Regulatory frameworks under consideration will likely build on these early successes, mandating AI- driven approaches as an integral part of postmarket surveillance systems to enhance the consistency and timeliness of pharmacovigilance activities.

Real-Word Evidence Frameworks

In parallel, real- world evidence (RWE) frameworks are poised to become a regulatory cornerstone in supplementing data from traditional clinical trials. [14] Post- 2020 regulations are expected to require that RWE from distributed database networks—such as those developed under the OHDSI and OpenSAFELY initiatives—be systematically integrated into safety assessments. These real- world data sources provide critical insights into

drug safety in routine clinical practice, capturing long-term outcomes, rare events, and signals that may not emerge during controlled trials. [15, 16]

The Italian VALORE project, for instance, exemplifies how linking claims data to disease registries can provide robust assessments of biologic safety across heterogeneous patient populations. This model shows the regulatory imperative to use RWE for confirming the safety profiles established in clinical trials and for continuously monitoring drugs in a real-world setting. [17]

Global Regulation Harmonization

Global harmonization represents another key future direction. The World Health Organization's Global Vaccine Safety Blueprint 2.0 is expected to expand its reach to include low-resource regions by enforcing standardized ADR reporting through mobile health (mHealth) platforms. Such standardization will facilitate the aggregation and analysis of safety data from regions that have traditionally been underrepresented in global pharmacovigilance systems. [18]

Moreover, cross-border data-sharing agreements modeled on initiatives like the European Union's ACCESS project are anticipated to emerge, leading to multinational pharmacoepidemiological studies. These efforts will help enhance the comparability of data across different healthcare systems while ensuring that safety signals are identified and addressed on a global scale, thereby strengthening the overall safety net around novel therapies. [17, 19]

Advanced Therapies & Risk Minimization

Advanced therapies, particularly advanced therapy medicinal products (ATMPs) such as gene and cell therapies, will necessitate the development of embedded risk minimization strategies. Regulatory agencies are expected to require comprehensive risk management plans (RMPs) that incorporate real-time safety monitoring systems. For example, wearable devices, including continuous glucose monitors, could be deployed to track metabolic adverse events in patients receiving gene therapies.

Such continuous monitoring allows for the rapid detection of adverse physiological changes, enabling preemptive intervention and fine-tuning of therapeutic protocols. This proactive approach will be especially critical in managing the unique risk profiles associated with ATMPs, where traditional monitoring frameworks may be insufficient. [19]

Patient-Centric Surveillance

Finally, a shift toward patient-centric surveillance is anticipated as part of future regulatory reforms. Recognizing that traditional spontaneous reporting systems often fail to capture subjective adverse events such as fatigue or pain, regulators will likely incentivize the development of validated mobile applications that empower patients to directly report their experiences. [20]

This approach addresses the issue of underreporting while enriching the pharmacovigilance dataset with patient-generated information that may provide early warnings of emerging safety issues. The European Medicines Agency's 2020 guidance on patient-reported outcomes (PROs) has set a precedent by formally integrating patient narratives into benefit-risk assessments. Future regulatory policies are expected to build on this foundation, further embedding patient-centric tools into pharmacovigilance frameworks to enhance the overall responsiveness and accuracy of drug safety monitoring. [21]

III. Recommendations

Mandate the Integration of Advanced AI/ML Tools for ADR Extraction and Signal Detection

Regulatory bodies such as the FDA should require that marketing authorization holders integrate AI-driven systems—specifically, models such as dynamic graph convolutional networks (e.g., the DySPred model with proven 89% precision for ICI-related myocarditis detection) and Bayesian neural networks—into postmarketing surveillance programs. These systems must be validated against established benchmarks (as set forth by the Sentinel Initiative) and incorporated into the Emerging Drug Safety Technology Program. Such a mandate would accelerate the identification of rare and delayed adverse drug reactions (ADRs) from multiple data sources, including electronic health records (EHRs), social media, and clinical narratives.

Require Real- World Evidence (RWE) Integration Through Distributed Data Networks

Future regulations should compel the use of RWE from networks like OHDSI and OpenSAFELY to complement clinical trial data. Specific performance metrics and quality standards should be defined in collaboration with initiatives such as the FDA's Sentinel System Five-Year Strategy (2019) and the Italian VALORE project, which has shown the statistical power of multi-database networks. Regulators must establish clear guidelines on data integration, curation, and analysis so that real- world safety signals can be reliably detected and addressed.

Establish Global Harmonization and Cross- Border Data-Sharing Protocols

To address disparities across regions, regulatory agencies should adopt a harmonized framework for ADR reporting. The expansion of the WHO Global Vaccine Safety Blueprint 2.0 to low-resource regions should be mandated along with adoption of the new international standard format for adverse reaction reporting (as already piloted in Italy with the new National Pharmacovigilance Network [RNF]). Furthermore, cross-border data-sharing agreements modeled on the EU's ACCESS project should be enforced to support multinational pharmacoepidemiological studies. This will enhance signal detection globally and ensure that safety standards are uniformly maintained.

Implement Specific Risk Minimization Requirements for Advanced Therapy Medicinal Products (ATMPs)

As advanced therapies (e.g., gene and cell therapies) present unique safety challenges, regulators must require that their risk management plans (RMPs) include embedded real-time safety monitoring. For example, the use of wearable devices (such as continuous glucose monitors for gene therapy recipients) should become a regulatory requirement. These devices can provide real-time physiological data, thereby enabling proactive intervention if adverse metabolic or cardiovascular events are detected.

Enhance Patient-Centric Surveillance Through Mandatory PRO Integration

Regulatory guidelines should mandate the deployment of validated patient-reported outcome (PRO) tools. Building on the EMA's 2020 guidance on integrating PROs into benefit–risk assessments, future regulations should require that pharmaceutical companies implement mobile applications and mHealth platforms that allow patients to report subjective ADRs (e.g., fatigue, pain) in real time. These tools should be integrated into broader pharmacovigilance systems to ensure that underreported events are captured and analyzed alongside traditional data sources.

Establish a Robust Quality Assurance Framework for Human-in-the-Loop AI Systems

Given that current AI/ML algorithms are not yet fully autonomous, regulators should require a formal quality assurance process when human experts are incorporated into the workflow. Specific measures might include risk-based thresholds that ensure no high-value reports are misclassified, periodic retraining and validation of AI models, and the use of independent rule-based algorithms as cross-checks. Detailed reporting of algorithm performance metrics (such as sensitivity, precision, and F1 scores) should be required as part of routine submissions, ensuring that the human-AI system meets or exceeds the performance of traditional methods.

IV. Conclusion

The ever-evolving requirements of oncology demands a reimagined approach to pharmacovigilance—one that transcends the limitations of traditional spontaneous reporting systems and short-term clinical trial data. The integration of advanced methodologies, such as AI-driven signal detection using dynamic graph convolutional networks, decentralized platforms for real-time patient-reported outcomes, genomic biomarker-enhanced databases, and proactive risk management strategies for combination therapies, represents a significant paradigm shift toward a more dynamic, accurate, and patient-centric model of drug safety monitoring.

These novel approaches promise to enhance early detection and rapid response to adverse drug reactions and offer the potential for personalized risk stratification, ultimately ensuring that novel cancer therapies are administered with the highest levels of safety and clinical efficacy. As these systems continue to evolve and integrate with real-world data, they pave the way for a future where proactive and comprehensive pharmacovigilance becomes the very foundation of effective oncology care, safeguarding patient health while supporting the advancement of precision medicine.

References

[1] A. Sawarkar, R. K. Sharma, V. Gautam, K. Shramankar, And N. Dinodia, "Pharmacovigilance: Present Status And Future Perspectives," The Pharma Innovation Journal, Vol. 8, No. 8, Pp. 84–92, 2019.
[2] G. Jetley, "Complexities Of Data, Tasks And Workflows In Health It Management," Ph.D. Dissertation, Univ. Of South Florida, 2020.
[3] B. A. Adenuga, D. Kibuule, K. D. S. Bamitale, And T. W. Rennie, "Effective Integration Of Pharmacovigilance Systems At Public Health Facilities In Resource-Limited Settings: A Qualitative Study," Research In Social And Administrative Pharmacy, Vol. 16, No. 8, Pp. 1111–1116, 2020.
[4] J. K. Jones And E. Kingery, "History Of Pharmacovigilance," In Mann's Pharmacovigilance, 2014, Pp. 11–24.
[5] G. Fornasier, S. Francescon, R. Leone, And P. Baldo, "An Historical Overview Over Pharmacovigilance," International Journal Of Clinical Pharmacy, Vol. 40, Pp. 744–747, 2018.
[6] M. A. Malikova, "Practical Applications Of Regulatory Requirements For Signal Detection And Communications In Pharmacovigilance," Therapeutic Advances In Drug Safety, Vol. 11, P. 2042098620909614, 2020.
[7] M. Schurer, L. Bam, And I. H. De Kock, "An Investigation Into The Value Of A Standardised Global Pharmacovigilance Reporting System," South African Journal Of Industrial Engineering, Vol. 28, No. 3, Pp. 78–88, 2017.
[8] G. J. Dal Pan, "Ongoing Challenges In Pharmacovigilance," Drug Safety, Vol. 37, Pp. 1–8, 2014.

[9] D. J. Lewis And J. F. Mccallum, "Utilizing Advanced Technologies To Augment Pharmacovigilance Systems: Challenges And Opportunities," Therapeutic Innovation & Regulatory Science, Vol. 54, No. 4, Pp. 888–899, 2020.
[10] R. Quick, "The Audit Expectation Gap: A Review Of The Academic Literature," Maandblad Voor Accountancy En Bedrijfseconomie, Vol. 94, No. 1/2, Pp. 5–25, 2020.
[11] C. Rijcken, Digital Therapeutic Mangroves, In Pharmaceutical Care In Digital Revolution, Academic Press, 2019, Pp. 169–179.
[12] A. Bate, A. Pariente, M. Hauben, And B. Bégaud, "Quantitative Signal Detection And Analysis In Pharmacovigilance," In Mann's Pharmacovigilance, 2014, Pp. 331–354.
[13] A. Bate, The Use Of A Bayesian Confidence Propagation Neural Network In Pharmacovigilance. Umeå, Sweden: Division Of Clinical Pharmacology, Dept. Of Pharmacology And Clinical Neuroscience, Umeå Univ., 2003. [Online]. Available: Https://Www.Diva-Portal.Org/Smash/Get/Diva2:144650/Fulltext01.Pdf
[14] J. Wise Et Al., "The Positive Impacts Of Real-World Data On The Challenges Facing The Evolution Of Biopharma," Drug Discovery Today, Vol. 23, No. 4, Pp. 788–801, 2018.
[15] K. A. Mc Cord, "The Use Of Routinely Collected Data In Clinical Trial Research," Ph.D. Dissertation, Univ. Of Basel, 2020.
[16] A. F. C. Smith, "Developing A Framework For Assessing The Impact Of Test Measurement Uncertainty On Clinical And Health-Economic Outcomes," Ph.D. Dissertation, Univ. Of Leeds, 2020.
[17] R. Gini Et Al., "Chronic Disease Prevalence From Italian Administrative Databases In The Valore Project: A Validation Through Comparison Of Population Estimates With General Practice Databases And National Survey," Bmc Public Health, Vol. 13, Pp. 1–11, 2013.
[18] World Health Organization, Global Vaccine Safety Blueprint 2.0 Background Research, No. Who/Mvp/Emp/Sav/2019.03, 2019.
[19] M. Nalin Et Al., "The European Cross-Border Health Data Exchange Roadmap: Case Study In The Italian Setting," Journal Of Biomedical Informatics, Vol. 94, P. 103183, 2019.
[20] A. Goula Et Al., "Advanced Therapy Medicinal Products Challenges And Perspectives In Regenerative Medicine," Journal Of Clinical Medicine Research, Vol. 12, No. 12, P. 780, 2020.
[21] P. Brown And P. Bahri, "'Engagement' Of Patients And Healthcare Professionals In Regulatory Pharmacovigilance: Establishing A Conceptual And Methodological Framework," European Journal Of Clinical Pharmacology, Vol. 75, Pp. 1181–1192, 2019.